IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUAL V - Media Centre | EASD
Novel insulin/GLP-1 combo succeeds in phase III trial | MDedge Endocrinology
Insulin Degludec Insulin Aspart (Novo Nordisk) | Bioz | Ratings For Life-Science Research
Frontiers | Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting
IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy – topic of research paper in Clinical medicine. Download scholarly article PDF and read for
Novo Nordisk invests $60 million in expansion of Kalundborg site
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes | Drugs
Positive Phase 3b study resutls for Xultophy announced
Combination of Novo Nordisk's Insulin degludec and Victoza Provides Synergistic Benefits in Late-Stage Trial
Presentan en México IDeglira para tratar la diabetes tipo 2 – Mundodehoy.com
Novo Nordisk debuts diabetes combo in Mexico - PMLiVE
Peter Falck Christens, Manager Biostatistics IdegLira, (Novo Nordisk) — Ministry of Music
Summary of the effects of iDegLira and iGlarLixi on postprandial... | Download Scientific Diagram
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes | Drugs
Ideglira (Novo Nordisk) | Bioz | Ratings For Life-Science Research
Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population - Liu - 2022 - Journal of Diabetes Investigation - Wiley Online Library
Novo Nordisk's GLP-1/insulin combination, Xultophy, Moves One Step Closer to Approval in Europe
Ideglira (Novo Nordisk) | Bioz | Ratings For Life-Science Research
IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes - ScienceDirect
Xultophy® 100/3.6 demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight vs basal-bolus therapy
Novo posts strong performance, but US pricing pressure grows | pharmaphorum
Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in
New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes
Physicians' real-world experience with IDegLira: results of a European survey | BMJ Open Diabetes Research & Care
Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared With Insulin Glargine U100 Plus Insulin Aspart in the U.S. - Endocrine Practice
US approval for Novo Nordisk's Xultophy/IDegLira as diabetes battle hots up
